Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Gaat deze nu eindelijk een keer los? Goed volume....staat nu 16% in de plus........
deze deed het gisteren erg goed met een groot volume. Deze komt eindelijk van de plaats!
80K gekocht op 0,15 en 0,16
Enorm volume al drie dagen. Dit bedrijf heeft GEEN schuld. TWST: What makes ADVENTRX a good investment? Mr. Culley: As investors begin to return to the micro-cap markets, I think that ADVENTRX offers them a lower-risk regulatory path, shorter timelines to major value-creating events and hopefully a good return on their investment. Our shares are widely held with significant trading volume, and we have an easy-to-understand story within a complex biotech space. I also think that much of our success next year will be driven by execution rather than by clinical risk. So as investors look at the health care sector, ADVENTRX is well poised to offer a comfortable place to make an investment in what is still a time of considerable uncertainty. TWST: Tell us about your background. Mr. Culley: I’m fortunate to have spent many years on both the research and business side of this industry. The first half of my career was spent conducting academic research and working on drug development for a biotech company, and I have a master’s degree in biochemistry from UC, Santa Barbara. The second half of my career was spent as a Director and Vice President of business development, and I have an MBA from Cornell University. Being able to jump with facility between business and science has proven invaluable to me in my current role. TWST: Is there anything that you’d like to add? Mr. Culley: I think ADVENTRX is going to have a bright future. We’re delivering on our goals, we’re realistic about the challenges we face, and our recent financing success demonstrates our ability to adapt and thrive in difficult environments. We’ve moved away from high-risk, new chemical entities and costly in-house R&D activities and are focused on a business model that we believe will deliver high-value branded products with a limited investment and fairly short timelines.
deze heeft duidelijk de weg naar boven gevonden.....
www.investorcalendar.com/IC/CEPage.as... Developing proprietary products for the treatment of cancer. Lead programs include ANX-530, a novel emulsion formulation of vinorelbine to treat advanced non-small cell lung cancer and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. Recent news: Raised approximately $9 million in 2Q09 and 3Q09 financings, providing sufficient capital to support operations well into 2010. Plans to submit NDA for ANX-530 by year-end 2009.
drop.io/anxresearch inlog guest: insider5
Kijk eens naar de chart. Extreme bullish.stockcharts.com/h-sc/ui?s=ANX&p=D&yr=... ----------------------------------------------------------- Taxotere sales $2bn. Patent expires in 2010. 74.125.95.132/search?q=cache:gkD-... Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis Annual sales approx $2bn. Patent expires in 2010. ---------------------------------------------------------------- Adventrx Inching Closer To NDA Filing Of Emulsion Formulation Of Chemotherapy Drug 12/20/2009 3:27 AM ET (RTTNews) - Within the next few days, Adventrx Pharmaceuticals Inc. (ANX: News ) is expected to submit its New Drug Application for ANX-530, a novel emulsion formulation of chemotherapy drug Navelbine (vinorelbine). If submitted, the filing will mark the first NDA submission for Adventrx' drug. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. According to the company, Navelbine, which, despite being a generic product for a number of years, still sells in excess of $200 million a year world-wide. Adventrx is planning to seek approval of ANX-530 for the same indications as Navelbine. Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemotherapeutic agent, Taxotere. Incorporated under the name Victoria Enterprises, Inc. in December 1995, the company began operations in 1996. The name was subsequently changed to "BioQuest, Inc." then to "Biokeys Pharmaceuticals, Inc." and finally to "ADVENTRX Pharmaceuticals, Inc." in May 2003. The company's common stock trades on the American Stock Exchange (Amex). --------------------------------------------------------- Biogen and Adventrx are Icahn children. Icahn's Denner just left to sit on Biogen board. Biogen needs more oncology products, and ANX is close to FDA approval. Culley openly speaks of being acquired. Win-win, no conflicts.
Ben aan het 'onderzoeken' waar deze naartoe zou kunnen uitbreken? Iemand een idee. $0,30 denk ik zelf aan (in eerste instantie) Of veel meer?
Aandeel BLIJFT stijgen. 10% in de laatste minuut (0.2 naar 0.22). Ik ben best lyrisch over dit fonds of word de zaak weer zwaar overdreven met het aankomende medicijn waarop men wacht op goedkeuring door FDA?
was wel erg benieuwd naar de motivatie van dhr. sander waarom deze zo hilarisch is over dit aandeel.... nou dan moet ik hem zelf maar pumpen... ;-)) After our expected pullback yesterday, traders are looking at another run up for Adventrx Pharmaceuticals Inc. (Amex:ANX). Within days, the company is expected to submit its New Drug Application for ANX-530, which is a novel emulsion formulation of the chemotherapy drug Navelbine (also known as vinorelbine). The filing is expected to be the first NDA submission for Adventrx, who lists Carl Icahn (one of the world's richest billionaire financier, corporate raider, and private investors) as one of its biggest shareholders. Navelbine, is approved by the FDA to treat advanced non-small cell lung cancer, and approved in Europe to treat non-small cell lung cancer and advanced or metastatic breast cancer. It sells in excess of $200 million a year world-wide. Adventrx' ANX-530 will attempt to compete for the same indications as Navelbine. Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemo agent, Taxotere. Shares have been rising steadily are trading up in anticipation of that news.
[Modbreak IEX]: Gelieve niet over elkaar te discussiëren, bericht is bij dezen verwijderd.]
Wat zijn we weer aardig vandaag... Heb een ordertje uitstaan voor 0,205, maar ondanks dat de koers er inmiddels onder ligt, heb ik ze toch niet binnen. Hoe kan dit? Het is geen pinkie..
Ah ik heb ze nu op 0,20 wel binnen.. vaag. Er gaan geruchten dat er binnenkort een NDA filing wordt gedaan en speculatie op mogelijk een partnership. Zou de koers flink op kunnen krikken.
[Modbreak IEX]: Gelieve niet over elkaar te discussiëren, bericht is bij dezen verwijderd.]
Demenkovets schreef:
Ah ik heb ze nu op 0,20 wel binnen.. vaag.
Er gaan geruchten dat er binnenkort een NDA filing wordt gedaan en speculatie op mogelijk een partnership. Zou de koers flink op kunnen krikken.
Wakkere Hendrik jij. Jij vertelt niks nieuws hoor! Mogelijk heb je wel beet met dit aandeel maar het is zeer speculatief. + ANX heeft een sterke balans momenteel + De omzetpotentie is hoog -De verwachtingen zijn mi overdreven hoog en kans op deceptie is zeker aanwezig.
Zeg ik ergens dat ik iets nieuws vertel dan? Sorry hoor mister alwetende..
[Modbreak IEX]: Gelieve niet over elkaar te discussiëren, bericht is bij dezen verwijderd.]
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
923,12
+0,48%
EUR/USD
1,0733
+0,26%
FTSE 100
8.142,15
-0,06%
Germany40^
18.159,10
+0,87%
Gold spot
2.319,04
-0,58%
NY-Nasdaq Composite
17.688,88
+0,12%
Stijgers
Dalers